Inovio Pharmaceuticals Inc vs Telus Corporation Ordinary Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M), while Telus Corporation Ordinary Shares trades at $8.11 (market cap $12.52B). The key difference: Telus Corporation Ordinary Shares is far larger — about 121.3× Inovio Pharmaceuticals Inc's market cap, and Telus Corporation Ordinary Shares pays a 6.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Telus Corporation Ordinary Shares for 0 Days on average.
| INO | TU | |
|---|---|---|
Market Cap | $103.19M | $12.52B |
Volume | 8,461,580 | 6,655,034 |
Sector | Health | Media |
52-Week High | $2.60 | $15.33 |
52-Week Low | $0.66 | $7.72 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $33.57B |
Dividend Yield | — | 6.59% |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Telus Corporation is a Canadian telecommunications company providing wireless, internet, television, and business connectivity services, with additional operations in digital healthcare through Telus Health and customer experience services through Telus Digital.
Read more on TU →